A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa (Q34330708)

1 August 2017

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. (English)

1 reference

1 August 2017

1 reference

10

0 references

author name string

Genmin Lu

1

1 reference

1 August 2017

Francis R DeGuzman

2

1 reference

1 August 2017

Stanley J Hollenbach

3

1 reference

1 August 2017

Mark J Karbarz

4

1 reference

1 August 2017

Keith Abe

5

1 reference

1 August 2017

Gail Lee

6

1 reference

1 August 2017

Peng Luan

7

1 reference

1 August 2017

Athiwat Hutchaleelaha

8

1 reference

1 August 2017

Mayuko Inagaki

9

1 reference

1 August 2017

Pamela B Conley

10

1 reference

1 August 2017

David R Phillips

11

1 reference

1 August 2017

Uma Sinha

12

1 reference

1 August 2017

language of work or name

English

0 references

publication date

3 March 2013

1 reference

1 August 2017

1 reference

1 August 2017

19

1 reference

1 August 2017

4

1 reference

1 August 2017

446-451

1 reference

https://scigraph.springernature.com/pub.10.1038/nm.3102

1 August 2017

0 references

cites work

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

1 reference

Apixaban versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.

21 January 2018

1 reference

Apixaban in patients with atrial fibrillation

21 January 2018

1 reference

Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content

21 January 2018

1 reference

Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents

21 January 2018

1 reference

Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents

21 January 2018

1 reference

Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature

21 January 2018

1 reference

Recombinant factor VIIa as an antidote for anticoagulant treatment

21 January 2018

1 reference

Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats

21 January 2018

1 reference

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

21 January 2018

1 reference

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood [...]

21 January 2018

1 reference

Expression, purification, and characterization of inactive human coagulation factor Xa (Asn322Ala419)

21 January 2018

1 reference

Mechanisms of glycosaminoglycan activation of the serpins in hemostasis

21 January 2018

1 reference

Identification of critical molecular interactions mediating heparin activation of antithrombin: implications for the design of improved heparin anticoagulants

21 January 2018

1 reference

Neutralization of the anticoagulant activity of low molecular weight heparin LU 47311 (Clivarin) in man by protamine chloride

21 January 2018

1 reference

Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin.

21 January 2018

1 reference

The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity

21 January 2018

1 reference

In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative

21 January 2018

1 reference

Rivaroxaban in patients with a recent acute coronary syndrome

21 January 2018

1 reference

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

21 January 2018

1 reference

Structure of the dihydrofolate reductase gene in Chinese hamster ovary cells

21 January 2018

1 reference

Splicing mutations in the CHO DHFR gene preferentially induced by (+/-)-3 alpha,4 beta-dihydroxy-1 alpha,2 alpha-epoxy-1,2,3,4- tetrahydrobenzo[c]phenanthrene

21 January 2018

1 reference

Activation of human factor X (Stuart factor) by a protease from Russell's viper venom

21 January 2018

1 reference

Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.

21 January 2018

1 reference

Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins

21 January 2018

1 reference

Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives

21 January 2018

1 reference

12 December 2020

Bleeding time in rats: a comparison of different experimental conditions.

1 reference

12 December 2020

Mechanism by which exosites promote the inhibition of blood coagulation proteases by heparin-activated antithrombin

1 reference

12 December 2020

Surface-dependent reactions of the vitamin K-dependent enzyme complexes

1 reference

12 December 2020

Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies

1 reference

12 December 2020

Autoproteolysis or plasmin-mediated cleavage of factor Xaalpha exposes a plasminogen binding site and inhibits coagulation

1 reference

12 December 2020

Kinetics of blood coagulation factor Xaalpha autoproteolytic conversion to factor Xabeta. Effect on inhibition by antithrombin, prothrombinase assembly, and enzyme activity

1 reference

12 December 2020

Incomplete Reversal of Enoxaparin-Induced Bleeding by Protamine Sulfate

1 reference

12 December 2020

Identifiers

DOI

10.1038/NM.3102

1 reference

1 August 2017

1 reference